Navigation Links
Life Sciences Fund grants awards to launch health research
Date:4/18/2008

biotechnology opportunities. The investigators will also expand outreach to physicians and people in Washington State who have Type 1 diabetes, MS and lupus to enhance access to innovative therapeutic clinical studies.

Organizations collaborating in this research are: University of Washington.

Richard Smith, Battelle, Pacific Northwest National Laboratory, $4,830,000

Program title: Next Generation Clinical Proteomics to Target Human Health Challenges

Program focus: To develop a new proteomics (the large-scale identification of all the proteins in a sample, e.g., blood) technology and apply it in search of blood biomarkers for liver disease and in subsequent use as a powerful tool in the study of cancer, diabetes, and other conditions.

The investigators will develop and apply new technology to find blood proteins that reveal the earliest signs of chronic liver disease. The goal is to establish a safer, non-invasive, easier diagnostic process for liver fibrosis than liver biopsy, allowing an earlier intervention at lower cost and reduced levels of illness and patient discomfort. In Washington State, more than 4,000 people are diagnosed annually with liver disease caused by hepatitis C virus (HCV). About half are cured with a cost of $13 million for diagnosis. This team's technology platform would enable earlier diagnosis of HCV and is projected to increase successful treatment rates by nearly ten percent. Integral to this program is the extension of the technology platform to address problems in other diseases and to make it commercially available for broad clinical use. Organizations collaborating in this research are: University of Washington.


'/>"/>

Contact: Dianne Needham
needham@lsdfa.org
206-732-6776
Life Sciences Discovery Fund
Source:Eurekalert

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Life Sciences Discovery Fund Awards $2.2 Million to Support New Solid-Tumor Research Program
2. IC Sciences Investigates Application of Narrative Sciences for Medical Informatics Instruments
3. Edwards Lifesciences Announces Retirement of Director Vernon Loucks
4. Edwards Lifesciences to Host Earnings Conference Call on April 22, 2008
5. IC Sciences Deepens Commitment to Pioneer Digital Informatics Instruments through New Medical Division
6. Leading Life Sciences Company Installs SafeMedias Network Security Management Appliance to Prevent Illegal Peer to Peer (P2P) File Sharing
7. Advanced Life Sciences to Host Conference Call to Discuss April 7th Meeting with FDA
8. Edwards Lifesciences Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan
9. Derma Sciences Raises $6.1 Million Through Private Placement
10. CJPS Enterprises to Expand Efforts of 21st Century Jobs Fund Life Sciences Pipeline
11. Derma Sciences to Report 2007 Fourth Quarter and Year-End Results on April 1, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 2Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 3Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 4Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 5Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 6Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 7Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 8Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 9Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 10Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 11Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 12Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 13Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010 14Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 1Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 2Midlife Heart Risk Factors Linked to Later Dementia 53613 1Midlife Heart Risk Factors Linked to Later Dementia 53613 2Midlife Heart Risk Factors Linked to Later Dementia 53613 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 1More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 2More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 3More Than One in Five 12 to 17 Year Olds Have Trouble Seeing in Class 53609 4